US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,452.20

-15.9185-1.08%

Number of Gainers:2

Number of Losers:9

Number of Flat:- -

PE:- -

High:1,466.38

Open:1,466.38

Low:1,435.13

Close:1,468.12

Loading ...

Viatris Inc. Announces Positive Results from Phase 3 VEGA-3 Trial for Presbyopia Treatment with MR-141

Viatris Inc - Mr-141 Shows Consistent Safety Profile, No Serious Adverse Events

THOMSON REUTERS

Viatris Announces Positive Top-Line Results From Second Pivotal Phase 3 Vega-3 Trial of Mr-141 in Presbyopia

THOMSON REUTERS

Viatris Inc - Targets FDA Application for Mr-141 in Second Half of 2025

THOMSON REUTERS

Calendar of U.S. Earnings Expected in the Week Ahead

Gilead put volume heavy and directionally bearish

Assembly Biosciences Says ABI-4334 Phase 1b Trial Showed 'Strong' Antiviral Activity in Chronic Hepatitis B

MT Newswires Live

Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration

Gilead lowers FY25 EPS view to $7.68-$8.07 from $7.70-$8.10

Gilead, Kymera enter license agreement for molecular glue degrader program

BRIEF-Gilead Sciences And Kymera Therapeutics Enter Into Exclusive Option And License Agreement

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue Cdk2 Degraders

THOMSON REUTERS

Gilead Sciences Inc - Kymera Eligible to Receive up to $750 Mln in Payments

THOMSON REUTERS

Gilead Sciences Inc - Deal Expected to Reduce Gilead's 2025 EPS by $0.02-$0.03

THOMSON REUTERS

Emergent BioSolutions Secures $62.4M ASPR Contract Modification

Applied DNA Sciences Inc. Announces Appointment of Kyle Lawrence to Long Island Capital Alliance's Board of Directors

Aptevo Therapeutics Appoints Baker Tilly as New Auditor Following Moss Adams Merger

Quest Diagnostics to Release Second Quarter 2025 Financial Results

Refile-Emergent BioSolutions Shares up 3.1% After US Awards Additional $62.4 Million for Botulism Treatment Stockpile Contract (Adds Dropped Word)

THOMSON REUTERS

Emergent BioSolutions Shares up 3.1% US Awards Additional $62.4 Million for Botulism Treatment Stockpile Contract

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1452.2035,"timestamp":1750881599999,"preClose":1468.122,"halted":0,"volume":19011514,"delay":0,"changeRate":-0.010843,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-15.918457,"latestTime":"06-25 16:00:00 EDT","open":1466.3818,"high":1466.3818,"low":1435.1344,"amount":880893043.284317,"amplitude":0.021284,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750944600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.861163,"peRate":60.876863,"turnoverRate":0.007112,"increases":2,"decrements":9,"flats":0,"marketCap":163327258088,"floatMarketCap":162659855504.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1466.3818,"amplitude":0.021284,"preClose":1468.122,"low":1435.1344,"pbRate":"3.861163","latestPrice":1452.2035,"volume":19011514,"delay":0,"open":1466.3818,"prevYearClose":1284.7982,"prevWeekClose":1480.6842,"prevMonthClose":1489.9341,"prevQuarterClose":1502.9401,"fiveDayClose":1472.2814,"twentyDayClose":1477.283,"sixtyDayClose":1498.3141,"secType":"PLATE","market":"US","turnoverRate":0.007112,"peRate":60.876863,"marketCap":163327258088,"floatMarketCap":162659855504.25,"timestamp":1750881599999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":2,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546784595","title":"Viatris Inc. Announces Positive Results from Phase 3 VEGA-3 Trial for Presbyopia Treatment with MR-141","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546784595?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935324,"startTime":"0","endTime":"0","summary":"Viatris Inc. has announced positive top-line results from the VEGA-3 trial, the second pivotal Phase 3 study evaluating MR-141  for treating presbyopia. The trial met its primary and all secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity without compromising distance vision. The safety profile was consistent with previous clinical trials, with no treatment-related serious adverse events reported. The study involved 545 patients and showed significant improvements in visual acuity compared to placebo. Viatris plans to submit an application to the U.S. FDA in the second half of 2025. Results from this study have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. publi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL9ss7Vj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","VTRS","BK4588","LU2087621335.USD","BK4583","BK4007","BK4585"],"gpt_icon":0},{"id":"2546845697","title":"Viatris Inc - Mr-141 Shows Consistent Safety Profile, No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2546845697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546845697?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935302,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA3FSFRN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4007","LU2087621335.USD","BK4583","LU1839511570.USD","VTRS"],"gpt_icon":0},{"id":"2546845517","title":"Viatris Announces Positive Top-Line Results From Second Pivotal Phase 3 Vega-3 Trial of Mr-141 in Presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2546845517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546845517?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA3FSFRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTRS","LU1839511570.USD","LU2087621335.USD","BK4585","BK4583","BK4007","BK4588"],"gpt_icon":0},{"id":"2546784561","title":"Viatris Inc - Targets FDA Application for Mr-141 in Second Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546784561?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA3FSFRN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","VTRS","BK4588","BK4585","LU1839511570.USD","BK4007","BK4583"],"gpt_icon":0},{"id":"2546678648","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2546678648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546678648?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:00","pubTimestamp":1750932000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·McCormick & Co                                 2Q       .65   6:30 AM. ·NIKE Inc. Class B                                4Q       .13   4:15 PM. ·Walgreens Boots Allnc                            3Q       .33   7:00 AM. ·Apogee Enterp Inc.                              1Q       .47   6:30 AM. ·MSC Indus Direct                                 3Q      1.03   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","LU0708994859.HKD","AMC","BK4212","GB00B4LPDJ14.GBP","LU2065169927.USD","LU2065170008.USD","BK4097","PRGS","BK4149","BK4137","BK4534","HIVE","LU0251131958.USD","FC","GP","LU0321505868.SGD","MKC","BK4108","AYI","BK4106","LU0690374615.EUR","BK4082","BK4104","GB00B4QBRK32.GBP","STZ","LU2065171311.SGD","AEMD","BK4152","LU2552382215.SGD","BK4226","LU1303367103.USD","APOG","LU0203345920.USD","BK4566","NKE","LU2065171402.SGD","LU0786609619.USD","MSM","CNXC","UNF","OESX","BK4023","WBA","LNN","BK4558","BK4583","BK4568","BK4561","MKC.V"],"gpt_icon":1},{"id":"2546241659","title":"Gilead put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2546241659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546241659?lang=en_us&edition=fundamental","pubTime":"2025-06-25 22:55","pubTimestamp":1750863315,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Gilead (GILD) with 8,856 puts trading, or 2x expected. Most active are 6/27 weekly 103 puts and 6/27 weekly 99 puts, with tot...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1674673428.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0320765992.SGD","LU0109394709.USD","BK4139","BK4585","LU0058720904.USD","LU1585245621.USD","BK4568","LU1571399168.USD","IE00BSNM7G36.USD","LU1066051498.USD","IE00B3T34201.USD","LU0823416689.USD","LU2468319806.SGD","SG9999015978.USD","BK4583","BK4578","LU1839511570.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","LU1778281490.HKD","BK4550","LU2087621335.USD","SG9999015945.SGD","BK4566","BK4532","IE0002270589.USD","BK4588","IE00BKVL7J92.USD","LU0234570918.USD","GILD","LU1674673691.USD"],"gpt_icon":0},{"id":"2546224800","title":"Assembly Biosciences Says ABI-4334 Phase 1b Trial Showed 'Strong' Antiviral Activity in Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2546224800","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546224800?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:12","pubTimestamp":1750857172,"startTime":"0","endTime":"0","summary":"Assembly Biosciences (ASMB) said Wednesday a phase 1b trial of its drug candidate ABI-4334 showed 'strong' antiviral activity in chronic hepatitis B patients.Two groups of 10 patients with different d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1674673428.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0320765992.SGD","LU0109394709.USD","BK4139","BK4585","LU0058720904.USD","LU1585245621.USD","BK4568","LU1571399168.USD","IE00BSNM7G36.USD","LU1066051498.USD","IE00B3T34201.USD","LU0823416689.USD","LU2468319806.SGD","SG9999015978.USD","BK4583","ASMB","BK4578","LU1839511570.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","LU1778281490.HKD","BK4550","LU2087621335.USD","SG9999015945.SGD","BK4566","BK4532","IE0002270589.USD","BK4588","IE00BKVL7J92.USD","LU0234570918.USD","GILD","LU1674673691.USD"],"gpt_icon":0},{"id":"2546212544","title":"Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2546212544","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546212544?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:31","pubTimestamp":1750851060,"startTime":"0","endTime":"0","summary":"Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera.The companies on Wednesday said the deal is aimed at speeding the development and commercialization of a novel molecular-glue-degrader, or MGD, program targeting a protein kinase known as CDK2, a key contributor to tumor growth.Kymera, a Watertown, Mass., clinical-stage biotechnology company, is eligible to receive up to $750 million in total payments under the agreement, including up to $85 million in upfront and potential option exercise payments, the companies said.Kymera will lead all research activities for the CDK2 program, while Foster City, Calif., biopharmaceutical company Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if it exercises its option to exclusively license the program.Gilead and Kymera said CDK2-directed MGDs are a new type of drug","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0320765992.SGD","BK4007","LU0109394709.USD","BK4139","BK4585","LU0058720904.USD","KYMR","LU1585245621.USD","BK4568","LU1571399168.USD","IE00BSNM7G36.USD","LU1066051498.USD","IE00B3T34201.USD","LU0823416689.USD","LU2468319806.SGD","SG9999015978.USD","BK4583","BK4578","LU1839511570.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","LU1778281490.HKD","BK4550","LU2087621335.USD","SG9999015945.SGD","BK4539","BK4532","BK4566","LENZ","IE0002270589.USD","BK4588","IE00BKVL7J92.USD","LU0234570918.USD","GILD","LU1674673691.USD"],"gpt_icon":0},{"id":"2546214066","title":"Gilead lowers FY25 EPS view to $7.68-$8.07 from $7.70-$8.10","url":"https://stock-news.laohu8.com/highlight/detail?id=2546214066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546214066?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:20","pubTimestamp":1750850438,"startTime":"0","endTime":"0","summary":"Consensus $7.98. The company said, “Gilead (GILD) does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-lowers-fy25-eps-view-to-7-68-8-07-from-7-70-8-10-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-lowers-fy25-eps-view-to-7-68-8-07-from-7-70-8-10-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","LU0823416689.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU1674673428.USD","LU2089984988.USD","LU1066051498.USD","LU1839511570.USD","BK4139","LU1778281490.HKD","BK4578","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0320765992.SGD","LU2087621335.USD","LU0109394709.USD","SG9999015952.SGD","LU1066053197.SGD","IE00BKVL7J92.USD","LU0058720904.USD","SG9999015945.SGD","BK4585","IE00BZ1G4Q59.USD","BK4568","BK4550","LU0234570918.USD","LU1430594728.SGD","LU0889565916.HKD","SG9999015978.USD","LU1674673691.USD","IE00BSNM7G36.USD","BK4566","IE0002270589.USD","LU1585245621.USD","BK4532","BK4583","LU0289739699.SGD","BK4588","IE00B19Z3581.USD","SG9999015986.USD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2546140232","title":"Gilead, Kymera enter license agreement for molecular glue degrader program","url":"https://stock-news.laohu8.com/highlight/detail?id=2546140232","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546140232?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:15","pubTimestamp":1750850125,"startTime":"0","endTime":"0","summary":"Gilead (GILD) and Kymera Therapeutics (KYMR) announced that they have entered into an exclusive option and license agreement to accelerate the deve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-kymera-enter-license-agreement-for-molecular-glue-degrader-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-kymera-enter-license-agreement-for-molecular-glue-degrader-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","IE00B7SZLL34.SGD","LU1674673691.USD","LU2089984988.USD","SG9999015978.USD","LU1585245621.USD","LU1571399168.USD","SG9999015952.SGD","BK4532","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU1066051498.USD","GILD","BK4578","LU0320765992.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","IE00BKVL7J92.USD","SG9999015986.USD","BK4585","BK4583","IE0002270589.USD","LU0109394709.USD","LU1674673428.USD","LU1066053197.SGD","KYMR","BK4139","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1778281490.HKD","LU2087621335.USD","BK4550","LU0889565916.HKD","BK4588","IE00B3T34201.USD","LU1839511570.USD","BK4566","LU0823416689.USD","BK4568","LU0234570918.USD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2546214825","title":"BRIEF-Gilead Sciences And Kymera Therapeutics Enter Into Exclusive Option And License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2546214825","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546214825?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:04","pubTimestamp":1750849440,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences And Kymera Therapeutics Enter Into Exclusive Option And License AgreementJune 25 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD SCIENCES AND KYMERA THERAPEUTICS ENTER INTO EXCLUSI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA7WWSMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","LU2089984988.USD","LU0823416689.USD","KYMR","LU1585245621.USD","LU0058720904.USD","IE00B3T34201.USD","BK4566","LU1066053197.SGD","BK4532","BK4578","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0289739699.SGD","BK4588","SG9999015986.USD","LU1430594728.SGD","BK4139","IE0002270589.USD","BK4568","LU2468319806.SGD","LU0320765992.SGD","SG9999015945.SGD","LU1839511570.USD","IE00B19Z3581.USD","SG9999015952.SGD","IE00B19Z3B42.SGD","LU0109394709.USD","LU1066051498.USD","LU0889565916.HKD","LU0234570918.USD","IE00BSNM7G36.USD","LU2087621335.USD","IE00BKVL7J92.USD","LU1674673428.USD","BK4585","BK4550","IE00B7SZLL34.SGD","LU1571399168.USD","BK4583","GILD","SG9999015978.USD"],"gpt_icon":0},{"id":"2546921105","title":"Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue Cdk2 Degraders","url":"https://stock-news.laohu8.com/highlight/detail?id=2546921105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546921105?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:00","pubTimestamp":1750849202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA7WWSMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","BK4566","BK4588","SG9999015945.SGD","IE00B7SZLL34.SGD","KYMR","LU0289739699.SGD","LU1674673428.USD","LU0109394709.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4139","IE00BSNM7G36.USD","LU2089984988.USD","IE00BKVL7J92.USD","LU1839511570.USD","LU1066051498.USD","LU1585245621.USD","LU2468319806.SGD","IE00B3T34201.USD","LU1778281490.HKD","BK4583","LU1066053197.SGD","BK4578","IE0002270589.USD","LU0234570918.USD","LU1430594728.SGD","SG9999015986.USD","BK4568","BK4550","LU0058720904.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU1674673691.USD","SG9999015952.SGD","SG9999015978.USD","GILD","LU0823416689.USD","IE00B19Z3581.USD","LU1571399168.USD","BK4585","BK4532"],"gpt_icon":0},{"id":"2546521109","title":"Gilead Sciences Inc - Kymera Eligible to Receive up to $750 Mln in Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2546521109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546521109?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:00","pubTimestamp":1750849202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA7WWSMV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE00B3T34201.USD","LU0058720904.USD","LU1778281490.HKD","BK4566","LU1066051498.USD","IE0002270589.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","BK4568","LU2468319806.SGD","SG9999015978.USD","IE00BSNM7G36.USD","LU0320765992.SGD","BK4585","IE00BZ1G4Q59.USD","BK4578","BK4532","IE00B19Z3B42.SGD","LU0823416689.USD","LU1585245621.USD","LU0889565916.HKD","LU0234570918.USD","LU1674673691.USD","BK4550","LU0289739699.SGD","LU0109394709.USD","SG9999015986.USD","GILD","KYMR","LU1571399168.USD","LU1066053197.SGD","LU2087621335.USD","LU2089984988.USD","SG9999015952.SGD","IE00B19Z3581.USD","BK4588","LU1430594728.SGD","LU1839511570.USD","LU1674673428.USD","SG9999015945.SGD","BK4583"],"gpt_icon":0},{"id":"2546110912","title":"Gilead Sciences Inc - Deal Expected to Reduce Gilead's 2025 EPS by $0.02-$0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2546110912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546110912?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:00","pubTimestamp":1750849202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA7WWSMV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU2089984988.USD","LU0289739699.SGD","IE00BSNM7G36.USD","LU0823416689.USD","IE00BKVL7J92.USD","BK4578","LU0889565916.HKD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","BK4585","LU1571399168.USD","GILD","LU1585245621.USD","SG9999015945.SGD","LU1066051498.USD","SG9999015978.USD","LU0320765992.SGD","BK4139","LU1778281490.HKD","BK4568","LU2087621335.USD","IE00B19Z3581.USD","BK4550","BK4588","IE00B7SZLL34.SGD","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","BK4532","BK4583","LU0109394709.USD","LU1674673691.USD","SG9999015986.USD","BK4566","KYMR","LU0058720904.USD","IE0002270589.USD","SG9999015952.SGD","LU0234570918.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"2546253238","title":"Emergent BioSolutions Secures $62.4M ASPR Contract Modification","url":"https://stock-news.laohu8.com/highlight/detail?id=2546253238","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546253238?lang=en_us&edition=fundamental","pubTime":"2025-06-25 04:32","pubTimestamp":1750797137,"startTime":"0","endTime":"0","summary":"Emergent Biosolutions ( ($EBS) ) has provided an update. On June 23, 2025, Emergent BioSolutions announced a $62.4 million contract modification wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-secures-62-4m-aspr-contract-modification?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-secures-62-4m-aspr-contract-modification?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4139","EBS","ASPR","BK4009"],"gpt_icon":0},{"id":"2546230288","title":"Applied DNA Sciences Inc. Announces Appointment of Kyle Lawrence to Long Island Capital Alliance's Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2546230288","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546230288?lang=en_us&edition=fundamental","pubTime":"2025-06-25 03:10","pubTimestamp":1750792216,"startTime":"0","endTime":"0","summary":"Applied DNA Sciences Inc. has announced the appointment of Kyle Lawrence to the Board of Directors of the Long Island Capital Alliance . With this appointment, the LICA Board has expanded to 14 members. Mr. Lawrence is currently a Partner at Falcon Rappaport & Berman LLP, where he co-chairs the Digital Assets Practice Group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL3C9bg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APDN","BK4121","BK4583"],"gpt_icon":0},{"id":"2545475284","title":"Aptevo Therapeutics Appoints Baker Tilly as New Auditor Following Moss Adams Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2545475284","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545475284?lang=en_us&edition=fundamental","pubTime":"2025-06-24 04:06","pubTimestamp":1750709168,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics Inc. has announced a change in its independent registered public accounting firm following the merger of Moss Adams LLP with Baker Tilly US, LLP, effective June 3, 2025. As a result, Moss Adams has resigned, and Baker Tilly has been appointed as the company's new independent auditor for the year ending December 31, 2025, effective June 23, 2025. During the transition, there were no disagreements or reportable events between Aptevo and Moss Adams concerning accounting principles or financial statement disclosures. Moss Adams has confirmed agreement with these statements in a letter to the Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL8fgh8s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4583","EBS","BK4139"],"gpt_icon":1},{"id":"2545443382","title":"Quest Diagnostics to Release Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2545443382","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545443382?lang=en_us&edition=fundamental","pubTime":"2025-06-23 22:53","pubTimestamp":1750690398,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire  on June 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLch7m3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854103824.USD","BK4588","BK4585","LU1854104046.USD","BK4196","BK4583","DGX","BK4567"],"gpt_icon":0},{"id":"2545410494","title":"Refile-Emergent BioSolutions Shares up 3.1% After US Awards Additional $62.4 Million for Botulism Treatment Stockpile Contract (Adds Dropped Word)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545410494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545410494?lang=en_us&edition=fundamental","pubTime":"2025-06-23 22:06","pubTimestamp":1750687602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nL8N3SQ1A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2545417752","title":"Emergent BioSolutions Shares up 3.1% US Awards Additional $62.4 Million for Botulism Treatment Stockpile Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2545417752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545417752?lang=en_us&edition=fundamental","pubTime":"2025-06-23 21:51","pubTimestamp":1750686715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SQ0PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4583","EBS"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}